Intercept Pharmaceuticals, a company focused on the development and commercialization of therapeutics for chronic liver disease, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering. Intercept originally filed confidentially on August 8, 2012. The New York, NY-based company, which was founded in 2002 and booked $3 million in sales for the 12 months ended 6/30/2012, plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch is the sole bookrunner on the deal. No pricing terms were disclosed.
